Overview

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company